60% of pharmaceutical and biological companies in Shenzhen reported good news, and some companies recorded triple-digit growth

【Pharmaceutical Network Industry News】 Analysts said that the industry results of pharmaceutical biology in the third quarter are worth optimizing
.
For example, Ping An Securities analysis believes that the risk of the pharmaceutical sector has been released in the near future, and with the epidemic being well controlled, the performance of the pharmaceutical industry in the third quarter is expected to achieve accelerated growth
.
It is reported that according to the industry classification of Shenwan, at least Mindray Medical, Zuoli Pharmaceutical, Furui Shares, Dian Diagnostics, Wanze Shares, Northeast Pharmaceutical, Yongan Pharmaceutical, Shin Kong Pharmaceutical, Dong'e Ejiao, Huadong Pharmaceutical, China Resources Sanjiu, Huaren Pharmaceutical, Kaipu Biologics, Kelun Pharmaceutical, Myriad Medical and other companies have released performance forecasts or reports
for the first three quarters 。 Among these enterprises, about 60% of the company's net profit increased by more than 50% year-on-year, including Zuoli Pharmaceutical, Furui Co.
, Ltd.
, Dian Diagnostics, Northeast Pharmaceutical, Yongan Pharmaceutical, Dong'e Ejiao, Kaipu Biologics, Kelun Pharmaceutical, etc.
, of which Northeast Pharmaceutical and other companies recorded a triple-digit year-on-year increase in net profit in the first three quarters, and their performance rose
sharply.
Among them, according to the performance forecast released by Northeast Pharmaceutical, the company will achieve a year-on-year increase of 351.
02%-449.
07% in the first three quarters of this year, about 115 million yuan to 140 million yuan
。 For the growth of performance, Northeast Pharmaceutical said that it is mainly because the company continues to strengthen enterprise management, and uses measures such as adjusting structure, technical research, process optimization, cost reduction and efficiency improvement, and improving financial management level to quantify refined management to various positions, so that benefits can be fully reflected in all links of supply, production and marketing; Actively carry out sales business, formulate differentiated marketing strategies, effectively enhance product competitiveness, and achieve significant growth in
sales revenue.
Yongan Pharmaceutical expects net profit in the first three quarters to increase by 93%-100% year-on-year to 159 million yuan to 165 million yuan
.
Yongan Pharmaceutical said that the year-on-year increase in performance in the third quarter of 2022 was mainly due to the significant increase
in the sales price of the company's main product taurine during the reporting period compared with the same period of the previous year.
It is reported that taurine is a chemical API, belongs to the chemical API industry, and can be used as a nutritional enhancer in food additives, and the main production areas of taurine are in China
.
Dong Ejiao expects to achieve a year-on-year increase in net profit attributable to shareholders of listed companies by 53%–86% in the first three quarters of 2022, about 460 million yuan to 560 million yuan
.
Dong Ejiao said that the company takes "value remodeling, business remodeling, organizational remodeling, and spiritual reshaping" as the guide, and uses digitalization to innovate customer operation models and activate endogenous power; Vigorously promote the construction of the top brand of "nourishing national treasure Dong Ejiao", fully implement brand awakening and brand renewal, and enhance brand potential; Firmly strengthen the core business, accelerate product innovation, consolidate core competitiveness, and achieve healthy growth
in performance.
CapBiotech expects the net profit attributable to shareholders of listed companies in the first three quarters of 2022 to increase year-on-year: 108.
68%-124.
14%, about 1.
35 billion yuan to 1.
45 billion yuan
.
The net profit attributable to shareholders of listed companies after deducting non-recurring profits and losses increased by 112.
37% to 128.
25% year-on-year, about 1.
337 billion yuan to 1.
437 billion yuan
.
It is reported that during the reporting period, the company's management conscientiously implemented the annual business plan formulated by the board of directors, continued to promote the integrated business model of "nucleic acid testing products + medical testing services", continued to implement the "nucleic acid 99 strategy" and "Kaipu B53 nucleic acid remote strategic service program", actively gave full play to the company's product technology and market advantages, and strengthened market expansion
.
According to the industry, behind the good results of a number of listed companies in the first three quarters, the fundamental upgrade
of the continuous expansion of the revenue scale and the continuous improvement of the profit level of the pharmaceutical and biological industry.
In addition, some analysts said that there is still room for growth in the current situation of the overall stability of the fundamentals of the pharmaceutical and biological industry and the recovery of market confidence, and there is a high probability of rotation between sub-sectors, and it is recommended to focus on medical devices, innovative drugs, medical services and retail terminals
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.